Cancer vaccines are back in fashion, thanks to Dendreon Corp.'s recent Phase III success with Provenge (sipuleucel-T) in prostate cancer, and encouraging data presented this weekend at the American Society of Clinical Oncology's annual meeting sent shares of several other cancer vaccine players skyrocketing. (BioWorld Today)
Elixir Pharmaceuticals Inc. signed a potential $500 million deal giving Novartis AG the option either to exclusively license worldwide rights to Elixir's ghrelin antagonist program for diabetes or to acquire the biotech outright. (BioWorld Today)
Cempra Pharmaceuticals Inc. raised $46 million in a Series C financing to continue clinical trials with the two antibiotic programs it licensed three years ago from Optimer Pharmaceuticals Inc. (BioWorld Today)
